The notion that B cell intrinsic STING signals do not support autoimmune progression in and of themselves, provides some reassurance that anti-cancer therapies relying on STING agonists, which are currently in development (56), will not pose a significant direct risk of breaking B cell tolerance. This evidence concerns the gene STING1 and cancer.